ASTELLAS PHARMA
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2010-04-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 10
- Registration Number
- NCT00909571
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 264
- Registration Number
- NCT00902980
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 205
- Registration Number
- NCT00902291
- Locations
- πΊπΈ
University of California San Diego Medical Center, La Jolla, California, United States
π¨π¦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
π¨π¦Juravinski Cancer Centre, Hamilton, Ontario, Canada
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
Completed
- Conditions
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT00901251
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 248
- Registration Number
- NCT00892749
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 152
- Registration Number
- NCT00889382
- Locations
- π·π΄
Clinical Caunty Hospital Mures, Mures, Romania
π¨πΏGeneral University Hospital, Department of Obstetrics and Gynecology, Prague, Czechia
π·π΄Institutul Oncologic Prof. Dr. Ion. Chiricuta Sectia de Oncologie Medicala, Cluj Napoca, Romania
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 240
- Registration Number
- NCT00885820
Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 442
- Registration Number
- NCT00870441
An Open Study Assessing Bioavailability of a Modified Formulation of Tacrolimus in Kidney Transplant Recipients
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 27
- Registration Number
- NCT00865137
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-05-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 511
- Registration Number
- NCT00863707
Β© Copyright 2024. All Rights Reserved by MedPath